Global Anti-Malarial Drugs Market Report 2018 Featuring Mylan Labs, Cipla & GlaxoSmithKline Plc

Dublin, Dec. 04, 2018 (GLOBE NEWSWIRE) -- The "Anti-Malarial Drugs Market" report has been added to's offering.

The Global Anti-Malarial Drugs market reached USD 742.5 Million in 2016 by registering a CAGR of 3.2% across the globe. Moreover, the market is expected to garner USD 1,049.5 Million by the end of 2027.

The Global demand for Anti-Malarial Drugs is increasing due to massive growth of healthcare industry across the globe. Further, increasing awareness about early symptoms, constant monitoring and easy availability of therapeutics is key growth driver for Global Anti-Malarial Drugs market over the forecast period.

Middle East & Africa is slated to account for a share of 51.0% by 2027 in the Anti-Malarial Drugs market Asia Pacific is slated to account for a market share of 30.2% by 2027 in the Anti-Malarial Drugs market. Further, the market is expected to account USD 317.0 Million by 2027 from USD 222.8 Million in 2016. China & India are the major contributor to the growth of Asia Pacific Anti-Malarial Drugs market.

Global Anti-Malarial Drugs market is segmented on the basis of Anti-Malarial Activity Tissue Schizonticides, Blood Schizonticides, Gametocytocides, Sporontocides & Others. Among these segments, Gametocytocides segment (60.3% share in 2016) occupies the largest market of Anti-Malarial Drugs across the globe.

Further, Global Gametocytocides segment is anticipated to reach USD 639.7 Million by the end of 2027 from USD 448 Million in 2016. Moreover, this segment is anticipated to flourish at a CAGR of 3.39% over the forecast period. In addition, Blood Schizonticides segment of Anti-Malarial Drugs is expected to achieve Y-o-Y growth rate of 3.4% in 2027 as compared to previous year.

In addition this, Global Anti-Malarial Drugs market is also segmented by Drug Chemistry. In Drug Chemistry segment, the 4-aminoquinolines segment is estimated to capture the highest market share during the forecast period. In end-user segment, the retail pharmacy segment is estimated to remain highest during the forecast period.

This segment contributed around 60% market share of total Anti-Malarial Drugs market in 2016. Further, this segment is projected to capture 61.1% market share by 2027. Further, retail pharmacy segment is projected to achieve Y-o-Y growth rate of 3.5% in 2027 as compared to previous year.

Mylan Labs, Cipla & GlaxoSmithKline Plc are some of the prominent players of Anti-Malarial Drugs market.

Key Topics Covered:

1. Executive Summary

2. Research Methodology

3. Risk Analysis
3.1. Demand Risk
3.2. Supply Risk

4. Recent Changes and Development in Anti-Malaria Drugs Market by Geography
4.1. New Product Development
4.2. Merger and Acquisition
4.3. Expansion and others

5. Top Countries with Highest demand for Anti-Malaria Drugs - By Region
5.1. North America
5.2. Europe
5.3. Asia-Pacific
5.4. Middle East & Africa

6. Global Anti-Malaria Drugs Market Size (USD Million) and Forecast, 2016-2027

7. Market Dynamics & Its Impact Analysis
7.1. Growth Drivers
7.2. Challenges
7.3. Trends
7.4. Opportunities

8. Global Market Segmentation Analysis
8.1. By Anti-Malarial Activity Market Size (USD Million) & Y-O-Y Growth Analysis (%), 2016-2027
8.2. By Drug Chemistry Market Size (USD Million) & Y-O-Y Growth Analysis (%), 2016-2027
8.3. By Distribution Channel Market Size (USD Million) & Y-O-Y Growth Analysis (%), 2016-2027
8.4. By Region Market Size (USD Million), Y-O-Y Growth & Share Analysis (%), 2016-2027

9. Porter's Five Force Model Analysis

10.Competitive Landscape
10.1. Competitive Positioning of Major Players in Global Anti-Malaria Drugs Market
10.2. Company Profiles

Companies Mentioned

  • Mylan Labs
  • Cipla
  • GlaxoSmithKline
  • Novartis
  • Roche
  • Bayer AG
  • Lincoln Pharmaceuticals
  • Strides Pharma Science
  • Glenmark Pharmaceuticals
  • Alliance Pharmaceuticals

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs


You May Also Like


National Harbor, MD, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Thousands of leading researchers and ...

Rexahn Announces $7.5 Million Registered Direct Offering

ROCKVILLE, Md., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) ...

Fibrocell Reports 2016 Financial Results and Recent Operational Highlights

EXTON, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene ...